FDA approves HERNEXEOS(R), the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option

The FDA granted zongertinib Breakthrough Therapy Designation for patients with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment. The FDA also awarded a Commissioner's National Priority ...

FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option

This press release is not intended for UK mediaHERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as ...
Spectrum News NY1

Four hurt in fire at Upper West Side apartment building, FDNY says

A four-alarm blaze broke out at a six-story apartment building on Manhattan's Upper West Side Tuesday morning, leaving three residents and one firefighter with minor injuries, officials said. FDNY and ...

Boehringer Ingelheim Limited: FDA approves HERNEXEOS, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option

This press release is not intended for UK media HERNEXEOS (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial1 Acceler ...